HOME >> BIOLOGY >> NEWS
Enzyme delivered in smaller package protects cells from radiation damage

SEATTLE, June 1 A University of Pittsburgh School of Medicine research team, collaborating with scientists from Stanford University, have developed a new, smaller gene therapy vector that may be effective in delivering a radioprotective enzyme systemically throughout the body which may spare healthy tissue the long-term consequences of therapeutic irradiation. These results are being presented at the 10th annual meeting of the American Society of Gene Therapy, being held May 30 to June 3 at the Washington State Convention & Trade Center, Seattle.

Combined with intensive chemotherapy, high dose whole-body irradiation often is given to patients with blood and lymphatic cancers to wipe out their bone marrow cells prior to subsequent transplantation of hematopoietic stem cells, bone marrow stem cells or peripheral blood progenitor stem cells. However, there is increasing concern that such high doses of radiation may have long-term negative effects on healthy tissues and organs, such as the kidney, liver and thyroid gland.

Based on previous studies showing that intravenous gene therapy delivery of the enzyme manganese superoxide dismutase (MnSOD) could protect mice from whole body irradiation, and in preparation for a potential clinical trial of systemic MnSOD in humans, the University of Pittsburgh and Stanford researchers, led by Joel S. Greenberger, M.D., professor and chair of the department of radiation oncology, University of Pittsburgh School of Medicine, delivered the human MnSOD enzyme into mouse hematopoietic progenitor cells using a newly constructed gene therapy vector called a "minicircle" plasmid.

To determine if the cells transfected with the MnSOD minicircle plasmid retained radioprotective capacity, they irradiated those cells as well as another cell line transfected with MnSOD in a full-sized plasmid. They also irradiated a parent mouse cell line that had not been transfected with MnSOD. After irradiation, the cells we
'"/>

Contact: Jim Swyers
SwyersJP@upmc.edu
412-657-4957
University of Pittsburgh Schools of the Health Sciences
1-Jun-2007


Page: 1 2

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Enzyme Engineering XIX
3. Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
4. Enzyme shreds Alzheimers protein
5. Enzyme defect leads to hyperinsulinism
6. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
7. Enzyme crystal structure reveals unexpected genome repair functions
8. Enzyme inhibitors block replication of SARS virus
9. Enzyme may be target for new anti-inflammatory compounds
10. Enzyme action creates protein linked to Alzheimers disease
11. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2019)... ... ... Mount Sinai researchers have discovered how the enzyme DNA polymerase delta works to ... a study published in Nature Structural & Molecular Biology, the team also reported how ... diseases. , “DNA polymerase delta serves as the duplicating machine for the millions to ...
(Date:9/30/2019)... ... September 30, 2019 , ... USDM Life Sciences ... life science organizations to accelerate innovation and maximize productivity, announces that David Blewitt ... What: Just 30 days to 21 CFR Part 11 compliance with Box, When: ...
(Date:9/25/2019)... ... September 25, 2019 , ... Modality Solutions, a ... on Inc. Magazine’s annual Inc. 5000 list, the most prestigious ranking of the ... Based on this growth, the Houston-based firm also ranked No. 47 in its ...
Breaking Biology News(10 mins):
(Date:9/24/2019)... , ... September 24, 2019 , ... ... cell company, has completed training and site qualification for clinical trial sites and ... recruitment and screening of potential clinical trial participants. , Clinical trial sites are ...
(Date:9/24/2019)... ... ... In the past three years, the National Science Foundation (NSF) has awarded ... of Mines & Technology that expands human understanding of the microbial world. The ... and yet strong layer which is commonly known as a biofilm. , The broad ...
(Date:9/17/2019)... ... 17, 2019 , ... Catalent, a global leader in clinical ... Asia Pacific (APAC) will present at the upcoming 3rd Annual Accelerating Clinical Trials ... On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will present “Singapore: APAC’s ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a ... announces today that the U.S. Patent and Trademark Office (USPTO) and European Patent ... drug class recommendations for hypertension treatment. , The patent applies to Geneticure’s ...
Breaking Biology Technology:
Cached News: